| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/04/2003 | WO2002064792A3 Molecules for disease detection and treatment |
| 09/04/2003 | WO2002055698A3 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 09/04/2003 | WO2002053775A3 Identification of genetic determinants of polymorphic cyp3a5 expression |
| 09/04/2003 | WO2002046220A3 Sequences upstream of the carp gene, vectors containing them and uses thereof |
| 09/04/2003 | WO2002032932A3 Urotensin-ii agonists and antagonists |
| 09/04/2003 | WO2002020769A9 Human and mouse targeting peptides identified by phage display |
| 09/04/2003 | WO2002015892A3 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 09/04/2003 | WO2002009760A9 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
| 09/04/2003 | WO2002003977A3 Combinations of statins, estrogenic agents and optionally estrogens |
| 09/04/2003 | WO2001085193A3 Method for promoting neovascularization using a tweak agonist and an angiogenic factor |
| 09/04/2003 | WO2001081622A3 Diagnosis of diseases associated with dna repair |
| 09/04/2003 | WO2001076451A3 Diagnosis of diseases associated with metabolism |
| 09/04/2003 | WO2001066595A9 Human fgf-23 gene and gene expression products |
| 09/04/2003 | WO2001057261A9 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 09/04/2003 | US20030167525 Desaturase genes and uses thereof |
| 09/04/2003 | US20030167033 Systems and methods for photodynamic therapy |
| 09/04/2003 | US20030166928 Central nervous system disorders, sleep disorders, eating disorders. sexual disorders, hypotensive agents |
| 09/04/2003 | US20030166926 Pyrroloazepine derivatives |
| 09/04/2003 | US20030166899 Antiinflammatory agents; antiarthritic agents; anticancer agents |
| 09/04/2003 | US20030166873 Endothelial growth factor; measuring binding to monoclonal antibodies; calibration |
| 09/04/2003 | US20030166872 Grafting antibodies to nucleic acids; anticancer agents, osteoporosis, vision defects, antiinflammatory agents, skin disorders |
| 09/04/2003 | US20030166859 Controlling cell proliferation, cell differentiation; anticancer agents |
| 09/04/2003 | US20030166730 Amide derivatives for the treatment of diseases mediated by cytokines |
| 09/04/2003 | US20030166725 Compounds active at the glucocorticoid receptor |
| 09/04/2003 | US20030166720 Administering a therapeutic combination comprising a first amount of a fibric acid derivative and a second amount of a cholesteryl ester transfer protein inhibitor effective for treatment of hyperlipidemic conditions |
| 09/04/2003 | US20030166712 Combinations of cholesteryl ester transfer protein inhibitors and HMG CoA reductase inhibitors for cardiovascular indications |
| 09/04/2003 | US20030166702 Contacting carvedilol and ethyl acetate to form a solution, and cooling the solution whereby a precipitate is formed; hypotensive agent |
| 09/04/2003 | US20030166701 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| 09/04/2003 | US20030166697 Divalent aromatic heterocyclic compounds useful in prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like |
| 09/04/2003 | US20030166694 Glycinamides |
| 09/04/2003 | US20030166690 Use of compounds for decreasing activity of hormone-sensitive |
| 09/04/2003 | US20030166689 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/04/2003 | US20030166685 Acid derivatives of benzene useful as anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer |
| 09/04/2003 | US20030166683 N-(4-carbamimidoyl-phenyl)-glycine derivatives |
| 09/04/2003 | US20030166680 For treating serine protease or dual-serine protease mediated disorders |
| 09/04/2003 | US20030166671 Amorphous polymorphic forms by grinding or pulverizing; having a distinctive X-ray powder diffraction pattern; anti-tumor and -carcinogenic agents; administered by mouth, intravenous injection and inhalation |
| 09/04/2003 | US20030166661 Administering a synergistic mixture of L-arginine and a type V phosphodiesterase enzyme inhibitor as an antispasmodic agent to induce vasodilation; treating of cardiac pathologies as well as sexual disorders such as erectile dysfunction |
| 09/04/2003 | US20030166659 Administering a sustained release drug dosage-form including >5.0% by weight ranolazine in no more than two tablets per dose to maintain ranolazine plasma levels at a >850 ng base/mL for >24 hours; methacrylic acid copolymer binder |
| 09/04/2003 | US20030166653 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 09/04/2003 | US20030166652 Chemical compounds |
| 09/04/2003 | US20030166650 E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents |
| 09/04/2003 | US20030166646 Nitric oxide synthase inhibitors such as 4-(morpholin-4-yl methyl)-4,5-dihydro-1,3-thiazol-2-ylamine, administered for prophylaxis of neurodegenerative diseases |
| 09/04/2003 | US20030166644 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 09/04/2003 | US20030166641 Heterocyclic amines such as 1-(3,4-methylenedioxyphenyl)-2-(5 -(3,4-dimethoxyphenyl)pyrimidin-2-yl)- 2,3,4,9-tetrahydro-1H-beta-carboline, used as enzyme inhibitors for prophylaxix of sexual disorders |
| 09/04/2003 | US20030166637 Amines such as 9-(4-(4-(benzothiazol-2-yl)-piperazin-1-yl)-butyl)-9H-fluorene-9-carboxylic acid (2,2,2-trifluoroethyl) amide, used as microsomal triglyceride transfer protein antagonists, to prevent atherosclerosis or hyperlipemia |
| 09/04/2003 | US20030166634 Amines such as 3,3,5,5-Tetramethyl-1-vinylcyclohexanamine hydrochloride, used as N-methyl-D-aspartate (NMDA), serotonin and nicotinic acetylcholine receptor antagonists |
| 09/04/2003 | US20030166633 Pyridinylimidazoles |
| 09/04/2003 | US20030166632 Method for treating a disease or condition responsive to opening of C1C-2 channel |
| 09/04/2003 | US20030166630 Amino acid derivatives and their use as medicines |
| 09/04/2003 | US20030166628 Drugs such as 3-(4-chlorobenzo(b)thiophen-2-yl)-5,6-dihydro-imidazo(2,1-b)thiazole, used as hydroxytryptamine and/or noradrenaline reuptake inhibitors; anxiolytic agents |
| 09/04/2003 | US20030166626 7-Hydroxyepiandrosterone having neuroprotective activity |
| 09/04/2003 | US20030166613 A macrocyclic diterpene plant extract for treating viral infections; A computer program product for storing the library information of candidate compounds |
| 09/04/2003 | US20030166590 Microsomal triglyceride transfer protein |
| 09/04/2003 | US20030166588 Splice-region antisense composition and method |
| 09/04/2003 | US20030166582 Aryl fused azapolycyclic compounds |
| 09/04/2003 | US20030166581 Coadministered with caffeine, for prevention of seizures; for treatment of Parkinson's/Alzheimer's disease; dietetics; smoking cessation |
| 09/04/2003 | US20030166577 Inhibitors for the blood-clotting factor xa |
| 09/04/2003 | US20030166569 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 09/04/2003 | US20030166559 Comprises tumor necrosis factor antagonist activity for treatment of autoimmune conditions |
| 09/04/2003 | US20030166556 Immunoregulator |
| 09/04/2003 | US20030166547 Inducing angiogenesis in a tissue in need of angiogenesis, comprising providing the tissue in need of angiogenesis with an angiogenically effective amount of a recombinant c-fos induced growth factor/vascular endothelial growth factor D |
| 09/04/2003 | US20030166546 Uses of THANK, a TNF homologue that activates apoptosis |
| 09/04/2003 | US20030166532 Annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation. |
| 09/04/2003 | US20030166300 Growth-related inflammatory and immune response protein |
| 09/04/2003 | US20030166277 Targeted vaccine delivery systems |
| 09/04/2003 | US20030166239 Bone morphogenic proteins; for regulating bone homeostasis, adiposity, and calcification of atherosclerotic plaques |
| 09/04/2003 | US20030166219 Mitogen-activated protein/extracellular signal-regulated kinases (MAP/ERK) |
| 09/04/2003 | US20030166187 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 09/04/2003 | US20030166029 Obtaining an inhibitor of antibody-mediated lipid oxidation; drug screening; hemolysis; anticholesterol agents; cardiovascular disorder therapy |
| 09/04/2003 | US20030165999 Selecting modulator capable of controlling proenzyme associated with preventing organ hypertrophy and arterial thickening; blood pressure; hypotensive agents |
| 09/04/2003 | US20030165924 Comprises nucleotide sequences transcribed in cells which accumulate multiple intracellular lipid droplets for diagnosing atherosclerosis |
| 09/04/2003 | US20030165565 Diltiazem; controlled release; presleep administering; cardiovascular disorders |
| 09/04/2003 | US20030165510 Antiinflammatory agents; anticancer agents; cholesterol binding protein |
| 09/04/2003 | US20030165506 Novel alpha-catenin expressed in heart and testis |
| 09/04/2003 | US20030165503 Vaccine for the treatment of atherosclerosis |
| 09/04/2003 | US20030165494 Rheumatic diseases; anticholesterol agents; cardiovascular disorders; multiple sclerosis |
| 09/04/2003 | US20030165459 Binding to tumor necrosis factor |
| 09/04/2003 | US20030165434 Delivery of polynucleotide agents to the central nervous system |
| 09/04/2003 | CA2696267A1 Methods for preventing or treating cardiac arrhythmia |
| 09/04/2003 | CA2477558A1 N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/04/2003 | CA2477283A1 Vascular therapeutic methods and compositions involving the reduction or prevention of c-jun mediated processes |
| 09/04/2003 | CA2477245A1 Bipolar trans carotenoid salts and their uses |
| 09/04/2003 | CA2477008A1 Substituted pyrimidinones and pyrimidinthiones |
| 09/04/2003 | CA2476994A1 Methods of extending corneal graft survival |
| 09/04/2003 | CA2476972A1 Pharmaceutical dosage form and method for the production thereof |
| 09/04/2003 | CA2476896A1 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| 09/04/2003 | CA2476846A1 Method for detection of leptin receptor ligands |
| 09/04/2003 | CA2476630A1 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof |
| 09/04/2003 | CA2476518A1 Compositions and methods for the treatment of immune related diseases |
| 09/04/2003 | CA2476316A1 Beta3-adrenergic receptor agonists |
| 09/04/2003 | CA2476173A1 Arylsulfone derivatives |
| 09/04/2003 | CA2475963A1 Methods of treating vascular disease |
| 09/04/2003 | CA2475653A1 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| 09/04/2003 | CA2475299A1 Thiazole derivatives as npy receptor antagonists |
| 09/04/2003 | CA2474793A1 2-methylthiazolidine-2,4-dicarboxylic acid and the salts thereof used for the treatment of neurodegenerative diseases |
| 09/04/2003 | CA2459155A1 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 09/03/2003 | EP1340979A2 Neuropeptide receptor and uses thereof |
| 09/03/2003 | EP1340811A2 Antibodies with specificity for multiple adhesion molecules |
| 09/03/2003 | EP1340759A1 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| 09/03/2003 | EP1340754A1 Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |